EAACI Congress 2025
BackTPS32 - Allergen immunotherapy 03
Saturday 14 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D2.153
Allergenicity and Immunogenicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy
D2.149
EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY
D2.163
Effectiveness and safety of Venom ImmunoTherapy (VIT) with “Rapid Cluster” induction protocol
D2.158
Epitope Analysis and Mutation Design in Jug r 1 for Hypoallergenic Walnut Immunotherapy
D2.155
Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy
D2.162
Low dose oral immunotherapy for children with severe cow's milk allergy
D2.157
Peanut allergen-loaded microneedle array patch modulates the immune response to peanut allergy in Balb/c and C3H/HeJ mouse model
D2.164
Pediatric bee venom allergy: family background matters
D2.166
Randomized Controlled Trial of Sublingual Immunotherapy for Egg Allergy
D2.159
Real-World Protective Effects of Epicutaneous Immunotherapy in Peanut-allergic Toddlers
D2.154
Real-life observational study on the effectiveness of a broad-spectrum allergen product in unresponsive pediatric patients
D2.150
Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom
D2.151
Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)
D2.152
Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)
D2.156
Study on the Effect of the Mucosal Vaccine MV130 on Innate Immunity Factors in School-Age Children
